Showing 1 - 10 of 1,387
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...
Persistent link: https://www.econbiz.de/10009522774
Persistent link: https://www.econbiz.de/10010485559
Persistent link: https://www.econbiz.de/10011409439
Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...
Persistent link: https://www.econbiz.de/10013068052
We evaluate the impact of a price cap regulation implemented in the Colombian pharmaceutical market between 2011 and 2014. To do so, we take advantage of a unique data set where we observe three sources of variation: i) differences across eighteen groups in the Anatomical Therapeutic Chemical...
Persistent link: https://www.econbiz.de/10013238087
Persistent link: https://www.econbiz.de/10012598467
Persistent link: https://www.econbiz.de/10012598470
Persistent link: https://www.econbiz.de/10012488757
Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch...
Persistent link: https://www.econbiz.de/10012457799
Persistent link: https://www.econbiz.de/10014229927